ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ALDX Aldeyra Therapeutics Inc

4.20
0.26 (6.60%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aldeyra Therapeutics Inc NASDAQ:ALDX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.26 6.60% 4.20 3.91 4.31 4.295 3.96 3.96 539,277 21:02:01

Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences

12/11/2019 1:00pm

Business Wire


Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the following healthcare investor conferences in November:

  • Stifel 2019 Healthcare Conference Lotte New York Palace Hotel New York, N.Y. Tuesday, November 19, 2019 Presentation time: 4:45 p.m. (ET)
  • Jefferies 2019 London Healthcare Conference London, U.K. Thursday, November 21, 2019 Presentation time: 11:40 a.m. (ET)/4:40 p.m. (GMT)

Live audio webcasts of these presentations can be accessed on the Investor Relations section of the Aldeyra Therapeutics website at https://ir.aldeyra.com. Replays will be available following the live events and will be archived on the website for 90 days.

About Aldeyra Therapeutics Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and SjÃgren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Corporate Contact: David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com

Investor & Media Contact: Scott Solomon Sharon Merrill Associates, Inc. Tel: 617-542-5300 ALDX@investorrelations.com

1 Year Aldeyra Therapeutics Chart

1 Year Aldeyra Therapeutics Chart

1 Month Aldeyra Therapeutics Chart

1 Month Aldeyra Therapeutics Chart

Your Recent History

Delayed Upgrade Clock